WHO Declares Obesity a Chronic Disease, Urges Lifelong GLP-1 Treatment

The World Health Organization (WHO) has issued new guidance on treating obesity as a chronic disease. It recommends long-term use of GLP-1 medications, such as semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound), alongside lifestyle changes. Over 1 billion people worldwide currently live with obesity, a number expected to double by 2030.

The WHO's updated advice stresses that obesity requires lifelong care. It calls for continuous use of GLP-1 drugs to help adults manage their weight, combined with healthy eating and exercise. These medications work by reducing hunger and making food less appealing, which can support better eating habits.

Resistance training is also highlighted to prevent muscle loss during rapid weight loss. The WHO warns that quick reductions in food intake without exercise can weaken muscles, making strength training essential.

However, major challenges remain in rolling out the guidance. High costs, limited drug supplies, and unequal global access create barriers. The organisation urges countries to prioritise fair and affordable treatment for those with the greatest medical need.

The WHO insists that medications alone will not solve the obesity crisis. It has asked member countries to 'reboot' their strategies, focusing on prevention, better treatment systems, and improved care capacity.

The guidance aims to reshape obesity treatment worldwide. It pushes for long-term medication use, lifestyle changes, and fairer access to care. Without systemic improvements, however, the WHO warns that rising obesity rates will continue to strain health systems.